Reliability of classifying multiple sclerosis disease activity using magnetic resonance imaging in a multiple

Edru Erbayat Altay1, Elizabeth Fisher, Stephen E Jones

  • 1Cleveland Clinic Mellen Center for Multiple Sclerosis Treatment and Research, 9500 Euclid Ave, Cleveland, OH 44195-5244, USA. rudickr@ccf.org

JAMA Neurology
|April 20, 2013
PubMed
Abstract

Insights

Clinician reliability in counting new magnetic resonance imaging (MRI) lesions for multiple sclerosis (MS) is variable, especially for enlarging T2 lesions. More accessible and robust image analysis methods are needed for MS patient monitoring in clinics.

Area of Science:

  • Neurology
  • Radiology
  • Medical Imaging

Background:

  • Multiple Sclerosis (MS) management relies on monitoring disease activity via MRI.
  • Assessing new lesions on MRI is crucial for treatment decisions.
  • Current clinical practice may have variability in MRI lesion interpretation.

Purpose of the Study:

  • To evaluate the consistency of new MRI lesion counts by clinicians in a multiple sclerosis specialty clinic.
  • To compare clinician interpretation with expert neuroradiologist and computer analysis.
  • To identify factors affecting inter-rater reliability in MRI lesion assessment.

Main Methods:

  • Observational study in a multiple sclerosis specialty clinic.
  • 85 patients with MS underwent brain MRI at baseline and 6 months.
  • New T2 lesions, enlarging T2 lesions, and gadolinium-enhancing lesions were analyzed by a neuroradiologist and 3 clinicians.

Main Results:

  • Highest agreement was for gadolinium-enhancing lesions, intermediate for new T2 lesions, and poor for enlarging T2 lesions.
  • Clinician raters differed from neuroradiologist/computer analysis in 18-25% of cases regarding MRI activity.
  • Image quality and head positioning variations significantly impacted new T2 lesion estimates.

Conclusions:

  • Inter-rater variability in new T2 lesion counts is a concern in clinical settings.
  • Standardized image acquisition may improve reliability but is often impractical.
  • Development of robust, accessible image analysis tools is essential for MS patient care and drug monitoring.